Beijing Beilu Pharmaceutical Total Liabilities
Beijing Beilu Pharmaceutical total liabilities. Based on the latest financial reports, Beijing Beilu Pharmaceutical (300016) has total liabilities worth CN¥852.80 Million CNY (≈ $124.79 Million USD) as of September 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Check financial resilience of Beijing Beilu Pharmaceutical to evaluate the company's liquid asset resilience ratio.
Total Liabilities of Beijing Beilu Pharmaceutical (2005–2024)
Total liabilities of Beijing Beilu Pharmaceutical from 2005 to 2024. This chart illustrates how Beijing Beilu Pharmaceutical's total liabilities have evolved over time, based on quarterly financial data. Explore 300016 long-term investment intensity to see how much of total assets are deployed in long-term investments.
Beijing Beilu Pharmaceutical Competitors by Total Liabilities
The table below lists competitors of Beijing Beilu Pharmaceutical ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Red River Bancshares Inc
NASDAQ:RRBI
|
USA | $2.93 Billion |
|
Guangan
SHG:600979
|
China | CN¥8.87 Billion |
|
SLR Investment Corp
NASDAQ:SLRC
|
USA | $1.58 Billion |
|
eXp World Holdings, Inc.
NASDAQ:AGNT
|
USA | $258.32 Million |
|
Olema Pharmaceuticals Inc
NASDAQ:OLMA
|
USA | $50.17 Million |
|
ADLINK Technology Inc
TW:6166
|
Taiwan | NT$7.22 Billion |
|
Skipper Limited
NSE:SKIPPER
|
India | Rs30.42 Billion |
|
Fitipower Integrated Technology Inc
TW:4961
|
Taiwan | NT$3.76 Billion |
Liability Composition Analysis (2005–2024)
This chart breaks down Beijing Beilu Pharmaceutical's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the complete balance sheet picture, see Beijing Beilu Pharmaceutical assets under control.
Liquidity & Leverage Metrics
Beijing Beilu Pharmaceutical Total Liabilities Ratios Explained
Beijing Beilu Pharmaceutical total liabilities ratios compare its liabilities with its current assets, cash and shareholder equity.
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 2.22 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.39 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.26 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Beijing Beilu Pharmaceutical's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Beijing Beilu Pharmaceutical (2005–2024)
The table below shows the annual total liabilities of Beijing Beilu Pharmaceutical from 2005 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-12-31 | CN¥1.15 Billion ≈ $167.99 Million |
+11.12% |
| 2023-12-31 | CN¥1.03 Billion ≈ $151.18 Million |
+15.78% |
| 2022-12-31 | CN¥892.27 Million ≈ $130.57 Million |
+9.05% |
| 2021-12-31 | CN¥818.22 Million ≈ $119.73 Million |
-14.37% |
| 2020-12-31 | CN¥955.50 Million ≈ $139.82 Million |
+451.32% |
| 2019-12-31 | CN¥173.31 Million ≈ $25.36 Million |
+108.99% |
| 2018-12-31 | CN¥82.93 Million ≈ $12.13 Million |
+15.74% |
| 2017-12-31 | CN¥71.65 Million ≈ $10.48 Million |
+31.71% |
| 2016-12-31 | CN¥54.40 Million ≈ $7.96 Million |
-53.66% |
| 2015-12-31 | CN¥117.39 Million ≈ $17.18 Million |
-51.22% |
| 2014-12-31 | CN¥240.67 Million ≈ $35.22 Million |
+293.50% |
| 2013-12-31 | CN¥61.16 Million ≈ $8.95 Million |
+2.56% |
| 2012-12-31 | CN¥59.64 Million ≈ $8.73 Million |
+79.71% |
| 2011-12-31 | CN¥33.19 Million ≈ $4.86 Million |
+343.20% |
| 2010-12-31 | CN¥7.49 Million ≈ $1.10 Million |
-57.46% |
| 2009-12-31 | CN¥17.60 Million ≈ $2.58 Million |
-33.62% |
| 2008-12-31 | CN¥26.52 Million ≈ $3.88 Million |
-48.36% |
| 2007-12-31 | CN¥51.36 Million ≈ $7.52 Million |
-5.07% |
| 2006-12-31 | CN¥54.10 Million ≈ $7.92 Million |
+26.55% |
| 2005-12-31 | CN¥42.75 Million ≈ $6.26 Million |
-- |
About Beijing Beilu Pharmaceutical
Beijing Beilu Pharmaceutical Co., Ltd. engages in the research, development, production, and sale of pharmaceutical products in China. The company provides contrast agents, such as gadopentetate meglumine injection, gadobutrol injection, and gadobenate meglumine injection for MRI contrast; and iohexol injection, iopamidol injection, and iodixanol injection for CT contrast, as well as glimepiride … Read more